KRM Ayurveda H1 profit more than doubles as margin expands
Key highlights
- KRM Ayurveda reported H1 FY27 PAT of Rs 17.23 crore, up 109.55% year on year.
- KRM Ayurveda’s H1 FY27 EBITDA margin increased 771.92 basis points to 34.95%.
- KRM Ayurveda reported Q2 FY27 total income of Rs 35.30 crore, up 48.08% year on year.
- KRM Ayurveda is adding an 80-bed hospital in Sector-47, Gurugram.
powered by IRIS

KRM Ayurveda Limited more than doubled profit after tax in H1 FY27 to Rs 17.23 crore, up 109.55% year on year, as its EBITDA margin increased 771.92 basis points to 34.95%. Total income rose 40.10% to Rs 68.17 crore for the half year ended September 30, 2026.
Know KRM Ayurveda inside out
Results, valuation, peers and who's buying, in one view.
How did KRM Ayurveda perform in H1 FY27?
KRM Ayurveda reported earnings growth that exceeded income growth in the first half of financial year 2027. Total income increased to Rs 68.17 crore from Rs 48.65 crore in H1 FY26, while earnings before interest, tax, depreciation and amortisation (EBITDA) rose to Rs 23.82 crore from Rs 13.25 crore. Profit after tax (PAT) increased to Rs 17.23 crore from Rs 8.22 crore.
The half-year comparison shows a change in earnings conversion. EBITDA margin rose to 34.95% from 27.23%, an increase of 771.92 basis points, or bps, where 100 bps equal one percentage point. PAT margin increased 837.80 bps to 25.28% from 16.90%, while earnings per share increased to Rs 8.10 from Rs 5.30.
Management said the H1 FY27 outcome reflected KRM Ayurveda’s operating model and focus on profitable growth. Its commentary linked the margin improvement to operating efficiency, although the announcement did not provide a numerical breakdown of costs, patient volumes, pricing or product mix behind the 771.92-bps EBITDA-margin increase.
What did KRM Ayurveda report for the September quarter?
KRM Ayurveda reported total income of Rs 35.30 crore in Q2 FY27, the quarter ended September 30, 2026, up 48.08% from Rs 23.84 crore in Q2 FY26. EBITDA increased 63.60% to Rs 11.26 crore from Rs 6.88 crore, while PAT rose 95.37% to Rs 8.15 crore from Rs 4.17 crore.
Q2 FY27 EBITDA margin reached 31.91%, compared with 28.88% in Q2 FY26, a rise of 302.62 bps. PAT margin was 23.08%, up 558.57 bps from 17.49%, and earnings per share rose to Rs 3.83 from Rs 2.69.
The quarterly income growth rate of 48.08% was higher than the 40.10% rate reported for H1 FY27. However, Q2 PAT growth of 95.37% and EBITDA growth of 63.60% were below the corresponding half-year increases of 109.55% and 79.81%, respectively.
What healthcare capacity is KRM Ayurveda adding?
KRM Ayurveda is adding an 80-bed Ayurveda and Panchakarma hospital at Sector-47, Gurugram, with an area of 27,500 square feet. The company said its existing 95-bed Sector-41 facility in Gurugram was operating at approximately 90% to 100% capacity.
The company also disclosed a 23-bed MSS Hospital in Pitampura, spanning 5,631 square feet and providing inpatient and outpatient services. KRM Ayurveda’s Karma Ayurveda Day Care Centre in Janakpuri commenced operations in April 2026 and covers approximately 2,760.90 square feet.
A further Karma Ayurveda Day Care Centre began operations in Vashi, Navi Mumbai, on September 3, 2026. The Vashi centre spans approximately 2,100 square feet and is operated under a five-year lease.
KRM Ayurveda reported National Accreditation Board for Hospitals & Healthcare Providers, or NABH, accreditation for five Panchakarma day-care centres. The Bengaluru accreditation is valid until May 2029, while the Dwarka, Patna, Noida and Gomti Nagar, Lucknow accreditations run until dates between June and August 2029. The company said the assessments cover infrastructure, clinical practices, patient-care protocols, quality-management systems and operating processes.
Got a follow-up? Ask IRIS
How is KRM Ayurveda extending its wellness business?
KRM Ayurveda acquired a 100% stake in Karma Nutravedics Private Limited for Rs 1 lakh. The subsidiary is intended to focus on nutraceuticals, dietary and health supplements, and allied wellness products, creating a dedicated platform for the company’s new wellness vertical.
KRM Ayurveda said the Rs 1 lakh transaction did not result in equity dilution for existing shareholders. Management described the business as part of its plan for an integrated Ayurvedic healthcare platform combining hospitals, day-care centres, clinical expertise and wellness products.
The company also entered into an agreement to sell a non-operational property at G.T. Karnal Road in New Delhi for aggregate consideration of approximately Rs 3.50 crore. Management said the proposed transaction supports asset utilisation and capital allocation, but the release did not disclose a completion date, the property's carrying value or a potential gain or loss.
KRM Ayurveda said its existing offering includes treatment solutions, tele-consultancy, product manufacturing and direct-to-consumer wellness solutions supported by digital healthcare initiatives. The announcement did not disclose financial targets, capital expenditure, or a timetable for the nutraceuticals and dietary-supplements business.
Conclusion
KRM Ayurveda’s H1 FY27 results show profit and EBITDA growing materially faster than total income. PAT increased 109.55% to Rs 17.23 crore and EBITDA rose 79.81% to Rs 23.82 crore, compared with 40.10% income growth, resulting in EBITDA and PAT margin increases of 771.92 bps and 837.80 bps from H1 FY26.
The next disclosed developments to watch are the addition of the 80-bed Sector-47 Gurugram hospital, the utilisation of newer Janakpuri and Vashi day-care centres, and progress on the proposed Rs 3.50 crore G.T. Karnal Road property sale. Management has also identified Karma Nutravedics as its platform for nutraceuticals and supplements, without disclosing a timetable or financial target for that business.


